Accesso libero

The role of polymorphisms in glutathione-related genes in asbestos-related diseases

Alenka Franko

Alenka Franko

  • Clinical Institute of Occupational Medicine, University Medical Centre LjubljanaLjubljana, Slovenia
  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Franko, Alenka
, 
Katja Goricar

Katja Goricar

Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Goricar, Katja
, 
Metoda Dodic Fikfak

Metoda Dodic Fikfak

  • Clinical Institute of Occupational Medicine, University Medical Centre LjubljanaLjubljana, Slovenia
  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Dodic Fikfak, Metoda
, 
Viljem Kovac

Viljem Kovac

  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
  • Institute of Oncology LjubljanaLjubljana, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Kovac, Viljem
 e 
Vita Dolzan

Vita Dolzan

Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Dolzan, Vita
  
26 gen 2021
The role of polymorphisms in glutathione-related genes in asbestos-related diseases's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Scarica la copertina
Categoria dell'articolo: Research Article
Pubblicato online: 26 gen 2021
Pagine: 179 - 186
Ricevuto: 09 nov 2020
Accettato: 02 dic 2020
DOI: https://doi.org/10.2478/raon-2021-0002
Parole chiave
© 2021 Alenka Franko, Katja Goricar, Metoda Dodic Fikfak, Viljem Kovac, Vita Dolzan, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Background

The study investigated the influence of GCLC, GCLM, GSTM1, GSTT1 and GSTP1 polymorphisms, as well as the influence of interactions between polymorphism and interactions between polymorphisms and asbestos exposure, on the risk of developing pleural plaques, asbestosis and malignant mesothelioma (MM).

Subjects and methods

The cross sectional study included 940 asbestos-exposed subjects, among them 390 subjects with pleural plaques, 147 subjects with asbestosis, 225 subjects with MM and 178 subjects with no asbestos-related disease. GCLC rs17883901, GCLM rs41303970, GSTM1 null, GSTT1 null, GSTP1 rs1695 and GSTP1 rs1138272 genotypes were determined using PCR based methods. In statistical analysis, logistic regression was used.

Results

GSTT1 null genotype was associated with the decreased risk for pleural plaques (OR = 0.63; 95% CI = 0.40–0.98; p = 0.026) and asbestosis (OR = 0.51; 95% CI = 0.28–0.93; p = 0.028), but not for MM. A positive association was found between GSTP1 rs1695 AG + GG vs. AA genotypes for MM when compared to pleural plaques (OR = 1.39; 95% CI = 1.00–1.94; p = 0.049). The interactions between different polymorphisms showed no significant influence on the risk of investigated asbestos-related diseases. The interaction between GSTT1 null polymorphism and asbestos exposure decreased the MM risk (OR = 0.17; 95% CI = 0.03–0.85; p = 0.031).

Conclusions

Our findings suggest that GSTT1 null genotype may be associated with a decreased risk for pleural plaques and asbestosis, may modify the association between asbestos exposure and MM and may consequently act protectively on MM risk. This study also revealed a protective effect of the interaction between GSTP1 rs1695 polymorphism and asbestos exposure on MM risk.

Lingua:
Inglese
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Medicina, Medicina clinica, Medicina interna, Ematologia, Oncologia, Radiologia
Feed RSS della rivista